Novoprotein(SH:688137)2025-10-29 10:30Revenue and Profitability - The company's revenue for Q3 2025 was CNY 39,760,343.29, representing a year-over-year increase of 22.63%[3] - The total profit for the year-to-date period was a loss of CNY 38,502,182.01, with a net loss attributable to shareholders of CNY 28,859,268.50[3] - Net profit for the first three quarters of 2025 was a loss of ¥28,859,268.50, compared to a loss of ¥18,258,535.09 in the same period of 2024, indicating a deterioration in performance[20] - Basic and diluted earnings per share for the first three quarters of 2025 were both -¥0.41, compared to -¥0.26 in 2024[21] Research and Development - Research and development expenses amounted to CNY 14,146,410.42 in Q3, accounting for 35.58% of total revenue, an increase of 0.60 percentage points compared to the previous year[4] - Research and development expenses increased to ¥40,248,363.71 in 2025 from ¥33,757,447.63 in 2024, marking a growth of 19.2%[19] Cash Flow and Financial Position - The net cash flow from operating activities for the year-to-date period was a negative CNY 17,498,412.32, reflecting a significant decline of 188.17%[3] - In the first three quarters of 2025, the net cash flow from operating activities was -$17.50 million, a decrease from $19.85 million in the same period of 2024[22] - Cash inflow from operating activities totaled $124.35 million in 2025, down from $158.59 million in 2024[22] - The company's cash and cash equivalents reached RMB 799.16 million as of September 30, 2025, an increase from RMB 647.35 million at the end of 2024[14] - Cash and cash equivalents at the end of Q3 2025 stood at $798.84 million, up from $668.39 million at the end of Q3 2024[23] Assets and Liabilities - The company's total assets at the end of the reporting period were CNY 2,195,238,545.78, a decrease of 1.03% from the end of the previous year[4] - The total assets as of the end of the reporting period were ¥2,195,238,545.78, slightly down from ¥2,218,110,499.82 in the previous year[16] - Total liabilities decreased to ¥114,781,644.07 from ¥116,442,779.95 year-over-year[16] Shareholder Information - The largest shareholder, Shanghai Xinbainuo Biotechnology Co., Ltd., holds 43.26% of the total shares, amounting to 30,355,000 shares[12] - Wujiang Dongyun Venture Capital Co., Ltd. is the second-largest shareholder with a 14.42% stake, holding 10,120,000 shares[12] - The company has a total of 6,094 common stock shareholders at the end of the reporting period[11] - The top ten shareholders collectively hold a significant portion of the company's shares, with the largest three shareholders accounting for over 62% of total shares[12] Government Subsidies and Financial Contributions - The company experienced a reduction in government subsidies, which contributed to the overall decrease in net profit and cash flow[9] - The total non-recurring gains and losses for the year-to-date period amounted to CNY 3,780,076.64, with significant contributions from government subsidies and financial asset valuations[7] Future Outlook and Strategy - The company is actively expanding into emerging business areas and increasing its R&D and marketing investments to achieve high-quality growth[8] - The company is focusing on expanding its market presence and enhancing product development strategies to improve future performance[19]